Fresenius Medical Care AG & Co. KGaA (FMS)
| Market Cap | 12.86B |
| Revenue (ttm) | 21.17B |
| Net Income (ttm) | 525.65M |
| Shares Out | 586.83M |
| EPS (ttm) | 0.90 |
| PE Ratio | 24.41 |
| Forward PE | 10.52 |
| Dividend | $0.63 (2.89%) |
| Ex-Dividend Date | May 17, 2024 |
| Volume | 407,341 |
| Open | 21.80 |
| Previous Close | 21.76 |
| Day's Range | 21.66 - 21.97 |
| 52-Week Range | 16.37 - 27.72 |
| Beta | 0.90 |
| Analysts | Hold |
| Price Target | 24.00 (+9.24%) |
| Earnings Date | May 7, 2024 |
About FMS
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized... [Read more]
Financial Performance
In 2023, FMS's revenue was 19.45 billion, an increase of 0.29% compared to the previous year's 19.40 billion. Earnings were 499.00 million, a decrease of -25.90%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FMS stock is "Hold." The 12-month stock price forecast is $24.0, which is an increase of 9.24% from the latest price.
News
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Today's Annual General Meeting was the first one following the change in legal form completed in November 2023 Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an incre...
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the p...
We have positive momentum in operating performance: Fresenius Medical Care CEO
Helen Giza, CEO of Fresenius Medical Care, joins CNBC's Annette Weisbach to discuss the company's 2024 first-quarter earnings results.
Fresenius Medical Care starts the year with strong earnings growth
Solid revenue1 growth of 4% driven by both segments Care Delivery and Care Enablement Operating income1 margin improved in both segments Care Enablement delivered strong sequential margin improvemen...
Fresenius Medical beats earnings expectations, keeps outlook; shares sink
Fresenius Medical Care beat first-quarter operating earnings expectations on Tuesday amid higher pricing and cost-cut savings, but the German company still maintained its profit outlook for 2024, send...
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care
Fresenius Medical Care delivers on commitments during a year of fundamental transformation Progress towards sustainability goals in key areas: patient satisfaction, diversity in management, climate ta...
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device
For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digi...
Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources
Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board role Jörg Häring contributes his extensive expertise from the energy, industry, and he...
Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador
Divestment of assets includes four separate country transactions to DaVita Inc. for USD 300 million Transactions further reduce the Company`s clinic footprint in Latin America, following the exit from...
Fresenius Medical Care delivers on commitments in a year of fundamental transformation
Revenue growth of 5% in 2023 driven by favorable business development Operating income1 growth of 15% exceeding top end of outlook range, due to business growth, FME25 savings ahead of plan and contri...
Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies
Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System. This will enable Fresenius Medical Care to offer the industry...
Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board
BAD HOMBURG, Germany , Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee ...
Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions
Divestments in 2023 are important milestones of the Company's execution against its Portfolio Optimization which are part of the set strategic aspirations Delivers on commitment to improve leverage ra...
Fresenius plans to sell rehabilitation care clinics - FAZ
Fresenius has hired UBS to manage the sale of its rehabilitation care clinic business as the German healthcare group focuses on core activities, Frankfurter Allgemeine Zeitung reported on Friday, citi...
Fresenius Medical Care says data on 500,000 people stolen in U.S.
Dialysis group Fresenius Medical Care said on Wednesday that data including medical records on 500,000 patients and former patients were stolen from a U.S. subsidiary's database.
Fresenius Medical Care completes change of legal form into a German stock corporation
Change of legal form simplifies the corporate governance structure as a German stock corporation (Aktiengesellschaft) The composition of the Management Board remains as before; the new Supervisory Boa...
Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx.
WALTHAM, Mass. , Nov. 21, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, resolved a legal dispute with the U.S....
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter
Continued solid organic growth in Care Enablement and Care Delivery including sequentially stable same market treatment growth in the U.S. Successful execution on turnaround plan driving productivity ...
Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery
WALTHAM, Mass. , Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as ne...
Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023
Company-wide research offers novel pathways for enhancing kidney patient care using data-driven insights and real-world evidence WALTHAM, Mass. , Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care, ...
Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset
Powerful Cloud-Based Data Asset to Drive Improvements in Care Quality and Patient Outcomes as the Largest Multinational, Longitudinal Database of its kind Achievement Part of Company's Long-Term AI St...
Capital Square Delivers 149.59% Total Return* to Investors in Medical Building DST
WINCHESTER, Va. , Oct. 18, 2023 /PRNewswire/ -- Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer and manager of multifamily commun...
Fresenius Medical: use of drugs like Ozempic has neutral effect on dialysis patient numbers
Germany's Fresenius Medical Care , said that use of Ozempic, and other diabetes and weight-loss drugs of the same class, would have an overall neutral effect on how many patients will require the comp...
What other industries could weight loss drugs disrupt?
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.